268 filings
Page 9 of 14
8-K
gsculbk12e5f31nqi
7 Nov 18
Zafgen Reports Third Quarter 2018 Operating and Financial Results
4:15pm
8-K
gnl0b3 olyrlielwlfl
7 Aug 18
Zafgen Reports Second Quarter 2018 Operating and Financial Results
4:21pm
8-K
97zmyk2u3y 8lsyrk0
2 Aug 18
Zafgen Announces Departure of President and Chief Scientific Officer Dr. Thomas Hughes
4:24pm
8-K
u1melpvnlj5spapywkew
28 Jun 18
Zafgen Announces Proposed Offering of Common Stock
5:01pm
424B5
drkl2dh4s1wyj0 kshs
28 Jun 18
Prospectus supplement for primary offering
4:54pm
424B5
cjgdzyvm3x20ao
27 Jun 18
Prospectus supplement for primary offering
4:49pm
8-K
5ow oqlrpjn7phmm1pd
25 Jun 18
Zafgen Announces Positive Full Results in Phase 2Proof-of-Concept Trial ofZGN-1061 in Patients withDifficult-to-Control Type 2 Diabetes
7:15am
8-K
x1j8it7 9f
7 Jun 18
Zafgen, Inc. Appoints Industry Veteran and Healthcare Policy Expert Dr. Wendy Everett to its Board of Directors
5:06pm
8-K
v0nlwuy
30 May 18
Zafgen, Inc. Expands Executive Leadership Team with Appointment of
5:17pm
8-K
2by16o83hcv5u6nd7qsc
8 May 18
Zafgen Reports First Quarter 2018 Operating and Financial Results
4:09pm
S-8
v9ofd
9 Mar 18
Registration of securities for employees
12:00am
8-K
fc0vwiz3kyu
6 Mar 18
Results of Operations and Financial Condition
12:00am
8-K
ele7 d5lsj6zut
5 Jan 18
Zafgen Reports Strong Clinical Progress and Updates Outlook for 2018
12:00am
8-K
efecre ir
7 Nov 17
Zafgen Reports Third Quarter 2017 Financial Results
12:00am
8-K
or3fqljgsmi49m 0m1
12 Oct 17
Zafgen Appoints Jeffrey Hatfield as Chief Executive Officer; Thomas Hughes, Ph.D. to Continue as President, Appointed Chief Scientific Officer
12:00am